Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Operating Leases (2019 - 2025)

Historic Operating Leases for Enanta Pharmaceuticals (ENTA) over the last 7 years, with Q4 2025 value amounting to $53.8 million.

  • Enanta Pharmaceuticals' Operating Leases fell 473.14% to $53.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was $53.8 million, marking a year-over-year decrease of 473.14%. This contributed to the annual value of $54.8 million for FY2025, which is 150.9% up from last year.
  • Enanta Pharmaceuticals' Operating Leases amounted to $53.8 million in Q4 2025, which was down 473.14% from $54.8 million recorded in Q3 2025.
  • In the past 5 years, Enanta Pharmaceuticals' Operating Leases ranged from a high of $56.5 million in Q1 2025 and a low of $1.1 million during Q3 2021
  • Over the past 5 years, Enanta Pharmaceuticals' median Operating Leases value was $22.4 million (recorded in 2022), while the average stood at $30.6 million.
  • Its Operating Leases has fluctuated over the past 5 years, first plummeted by 7066.18% in 2021, then soared by 188685.61% in 2022.
  • Enanta Pharmaceuticals' Operating Leases (Quarter) stood at $16.0 million in 2021, then soared by 36.98% to $21.9 million in 2022, then dropped by 6.11% to $20.5 million in 2023, then soared by 175.06% to $56.5 million in 2024, then fell by 4.73% to $53.8 million in 2025.
  • Its Operating Leases was $53.8 million in Q4 2025, compared to $54.8 million in Q3 2025 and $55.7 million in Q2 2025.